Aardvark Therapeutics, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Tien-Li Lee
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4370 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Feb 13, 2025
- CIK
- 0001774857
- Website
- aardvarktherapeutics.com
- Similar Companies
- Business
- Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that activate innate homeostatic pathways to suppress hunger for the treatment of metabolic diseases including Prader-Willi Syndrome (PWS) hyperphagia, obesity, and obesity-related conditions; the company offers ARD-101, an oral TAS2R bitter taste receptor agonist in Phase 3 clinical development primarily for hyperphagia in PWS via localized gut hormone release and gut-brain signaling to inhibit hunger discomfort; ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor advancing into two Phase 2 trials (POWER and STRENGTH) to address GLP-1RA limitations such as weight regain post-discontinuation through weight maintenance and loss promotion; and exploratory programs like WE-868 targeting hunger-associated indications and complementary anti-appetite therapies. Founded in 2017 and headquartered in San Diego, California, Aardvark Therapeutics operates principally in the United States with a pipeline directed at endocrinology and rare genetic disorders, targeting patients with insatiable hunger in PWS and broader metabolic obesity markets. Recent developments include presentation of positive ARD-101 clinical data and ARD-201 preclinical results at ObesityWeek 2025 demonstrating metabolic benefits; reporting of third-quarter 2025 financial results with pipeline updates advancing Phase 2 trials for ARD-201; an oversubscribed $85 million Series C financing in May 2024 led by Decheng Capital to support clinical progression; a $29 million Series B funding in 2021 led by Sorrento Therapeutics; Nasdaq debut in February 2025; and inducement grants under NASDAQ rules in 2025 to bolster executive talent.
Company News
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
AARD DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
AARD DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
AARD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf
AARD FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD